|
[1]
|
Tsochatzis, E.A., Bosch, J. and Burroughs, A.K. (2014) Liver Cirrhosis. The Lancet, 383, 1749-1761. [Google Scholar] [CrossRef]
|
|
[2]
|
Bishnu, S., Ahammed, Sk.M., Sarkar, A., et al. (2018) Ef-fects of Atorvastatin on Portal Hemodynamics and Clinical Outcomes in Patients with Cirrhosis with Portal Hypertension: A Proof-of-Concept Study. European Journal of Gastroenterology & Hepatology, 30, 54-59. [Google Scholar] [CrossRef]
|
|
[3]
|
Uschner, F.E., Ranabhat, G., Choi, S.S., et al. (2015) Statins Activate the Canonical Hedgehog-Signaling and Aggravate Non-Cirrhotic Portal Hypertension, But Inhibit the Non-Canonical Hedgehog Signaling and Cirrhotic Portal Hypertension. Scientific Reports, 5, Article No. 14573. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Xie, G.H., Choi, S.S., Syn, W.-K., et al. (2013) Hedgehog Signalling Reg-ulates Liver Sinusoidal Endothelial Cell Capillarisation. Gut, 62, 299-309. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Pollo-Flores, P., Soldan, M., Santos, U.C., et al. (2015) Three Months of Simvastatin Therapy vs. Placebo for Severe Portal Hypertension in Cirrhosis: A Randomized Controlled Trial. Digestive and Liver Disease, 47, 957-963. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Mohanty, A., Tate, J.P. and Garcia-Tsao, G. (2016) Statins Are Associated with a Decreased Risk of Decompensation and Death in Veterans with Hepatitis C-Related Compensated Cirrhosis. Gastroenterology, 150, 430-440.E1. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
D’Amico, G., Garcia-Tsao, G. and Pagliaro, L. (2006) Natural History and Prognostic Indicators of Survival in Cirrhosis: A Systematic Review of 118 Studies. Journal of Hepatology, 44, 217-231. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Jepsen, P., Ott, P., Andersen, P.K., et al. (2010) Clinical Course of Alcoholic Liver Cirrhosis: A Danish Population-Based Cohort Study. Hepatology, 51, 1675-1682. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Tapper, E.B., Jiang, Z.G. and Patwardhan, V.R. (2015) Refining the Am-monia Hypothesis: A Physiology-Driven Approach to the Treatment of Hepatic Encephalopathy. Mayo Clinic Proceed-ings, 90, 646-658. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Huang, H.-C., Chang, C.-C., Wang, S.-S., et al. (2012) Pravas-tatin for Thioacetamide-Induced Hepatic Failure and Encephalopathy. European Journal of Clinical Investigation, 42, 139-145. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Ferlay, J., Shin, H.-R., Bray, F., et al. (2010) Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127, 2893-2917. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Jemal, A., Bray, F., Center, M.M., et al. (2011) Global Cancer Statistics. CA: A Cancer Journal for Clinicians, 61, 69-90. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Hoshida, Y., Fuchs, B.C. and Tanabe, K.K. (2012) Prevention of Hepatocellular Carcinoma: Potential Targets, Experimental Models, and Clinical Chal-lenges. Current Cancer Drug Targets, 12, 1129-1159. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Higashi, T., Friedman, S.L. and Hoshida, Y. (2017) Hepatic Stellate Cells as Key Target in Liver Fibrosis. Advanced Drug Delivery Reviews, 121, 27-42. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Kwak, B., Mulhaupt, F., Myit, S., et al. (2000) Statins as a Newly Recognized Type of Immunomodulator. Nature Medicine, 6, 1399-1402. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Okada, Y., Yamaguchi, K., Nakajima, T., et al. (2013) Rosuvastatin Ameliorates High-Fat and High-Cholesterol Diet-Induced Nonalcoholic Steatohepatitis in Rats. Liver International, 33, 301-311. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Relja, B., Meder, F., Wilhelm, K., et al. (2010) Simvastatin Inhibits Cell Growth and Induces Apoptosis and G0/G1 Cell Cycle Arrest in Hepatic Cancer Cells. International Journal of Molecular Medicine, 26, 735-741. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Cao, Z.W., Fan-Minogue, H., Bellovin, D.I., et al. (2011) MYC Phosphorylation, Activation, and Tumorigenic Potential in Hepatocellular Carcinoma Are Regulated by HMG-CoA Re-ductase. Cancer Research, 71, 2286-2297. [Google Scholar] [CrossRef]
|
|
[19]
|
Jha, P. and Das, H. (2017) KLF2 in Regulation of NF-κB-Mediated Immune Cell Function and Inflammation. International Journal of Molecular Sciences, 18, Article 2383. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Marrone, G., Maeso-Díaz, R., García-Cardena, G., et al. (2015) KLF2 Exerts Antifibrotic and Vasoprotective Effects in Cirrhotic Rat Livers: Behind the Molecular Mechanisms of Statins. Gut, 64, 1434-1443. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Chong, L.-W., Hsu, Y.-C., Lee, T.-F., et al. (2015) Fluvastatin Attenuates Hepatic Steatosis-Induced Fibrogenesis in Rats through Inhibiting Paracrine Effect of Hepatocyte on Hepatic Stellate Cells. BMC Gastroenterology, 15, Article No. 22. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Mullen, P.J., Yu, R., Longo, J., et al. (2016) The Interplay between Cell Signalling and the Mevalonate Pathway in Cancer. Na-ture Reviews Cancer, 16, 718-731. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Hanai, J., Doro, N., Sasaki, A.T., et al. (2012) Inhibition of Lung Cancer Growth: ATP Citrate Lyase Knockdown and Statin Treatment Leads to Dual Blockade of Mitogen-Activated Protein Kinase (MAPK) and Phosphatidylinositol-3-Kinase (PI3K)/AKT Pathways. Journal of Cellular Physiology, 227, 1709-1720. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Docrat, T.F., Nagiah, S., Krishnan, A., et al. (2018) Atorvastatin Induces MicroRNA-145 Expression in HEPG2 Cells via Regulation of the PI3K/AKT Signalling Pathway. Chemico-Biological Interactions, 287, 32-40. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Smit, J., López-Cortés, L.E., Thomsen, R.W., et al. (2017) Statin Use and Risk of Community-Acquired Staphylococcus aureus Bacteremia: A Population-Based Case-Control Study. Mayo Clinic Proceedings, 92, 1469-1478. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Nseir, W., Mograbi, J., Khateeb, J., et al. (2012) The Impact of Prior Long-Term versus Short-Term Statin Use on the Mortality of Bacteraemic Patients. Infection, 40, 41-48. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Motzkus-Feagans, C., Pakyz, A.L., Ratliff, S.M., et al. (2013) Statin Use and Infections in Veterans with Cirrhosis. Alimentary Pharmacology & Therapeutics, 38, 611-618. [Google Scholar] [CrossRef] [PubMed]
|